title: [Temporal lobe epilepsy and active neurocysticercosis: two representative case reports].
abstract: BACKGROUND
  There are limited evidences reported of temporal lobe epilepsy associated with active cysticercosis in cystic stage. The objective is to present the correlation between active cysticercosis in topographical zones associated with temporal lobe epilepsy, with neuropsychiatric manifestations and pattern of secondarily generalized partial seizures.
  
  
  METHODS
  Two cases of adult patients with neuropsychiatric manifestations of one year evolution, refractory to antipsychotic drug treatment, and who subsequently appear late onset partial-secondarily generalized seizures. Cysticercosis active presence in the temporal lobe in one patient, and the insula in the other, is identified. A better clinical control after albendazol treatment and subsequently anticonvulsant therapy only remained to evaluate pertinence of pharmacological withdrawal criteria.
  
  
  CONCLUSIONS
  Active neurocysticercosis, may be the cause of acquired neuropsychiatric disorders and temporal lobe epilepsy of late onset when the topography is in the mesolimbic circuit. Early etiologic diagnosis and appropriate treatment allows adequate control of their symptoms and potentially final cure.
authors.affiliation: Universidad de Guadalajara. Centro Universitario de Ciencias de la Salud (CUCS), Guadalajara, Mexico.
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Ramos-Zúñiga
authors.forename: Héctor R
authors.initials: HR
authors.lastname: Pérez-Gómez
authors.forename: Luis A
authors.initials: LA
authors.lastname: Gaytán-Martínez
authors.forename: Brenda
authors.initials: B
authors.lastname: Vega-Ruiz
authors.forename: Sofía
authors.initials: S
authors.lastname: Soto-Rodríguez
authors.forename: Alejandro
authors.initials: A
authors.lastname: Rochín-Mozqueda
mesh_terms: D015766:Albendazole / Q000627:therapeutic use; D000849:Anomia / Q000188:drug therapy / Q000209:etiology*; D000871:Anthelmintics / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002220:Carbamazepine / Q000031:analogs & derivatives / Q000627:therapeutic use; D015283:Citalopram / Q000627:therapeutic use; D057210:Delayed Diagnosis; D003866:Depressive Disorder / Q000188:drug therapy / Q000209:etiology; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy / Q000209:etiology*; D006261:Headache / Q000209:etiology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D020019:Neurocysticercosis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D000078330:Oxcarbazepine; D016584:Panic Disorder / Q000188:drug therapy / Q000209:etiology*; D010546:Perphenazine / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use
chemical_list: D000871:Anthelmintics; D000927:Anticonvulsants; D014150:Antipsychotic Agents; D015283:Citalopram; D002220:Carbamazepine; D015766:Albendazole; D010546:Perphenazine; D011241:Prednisone; D000078330:Oxcarbazepine